文献速递消化与肝胆胰病理细胞病理与分子病理

细胞学评估可预测转移性胰腺神经内分泌肿瘤患者生存

Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
PubMed 文献 · Cancer Cytopathol · 2017-01-17

该研究对44例转移性胰腺神经内分泌肿瘤患者比较细胞学与同步空芯针活检在分化程度和Ki-67分级上的一致性,并将细胞学特征与生存关联。细胞学分化与分级均为结局的强预测因素,尽管细胞学分级与空芯针活检分级的一致性有限。

要点

  • 细胞学分化与分级可预测转移性胰腺神经内分泌肿瘤的生存。
  • 细胞学与空芯针活检的分化一致性较高,但分级一致性有限。
  • 细胞学分级为1、2、3级的中位疾病特异性生存分别为121、45、19个月。

核心结论

  • 细胞学分级与同步空芯针活检分级可能不完全一致,但基于分期校正分析,细胞学分化与分级可预测生存。

研究设计与样本

  • 对44例转移性胰腺神经内分泌肿瘤患者,比较同步空芯针活检与细胞学标本的分化、Ki-67分级及其与生存的相关性。

主要发现

  • 细胞学涂片分化结果为高分化38例(86%)、低分化6例(14%)。
  • 涂片与细胞块、涂片与空芯针活检、细胞块与空芯针活检的分化一致率分别为88%、94%、83%,分级一致率分别为68%、54%、22%。
  • 细胞学分化与细胞学分级均为结局的强预测因素,风险比分别为8.3(95%CI 3.1-22.1;P<.001)和每升高一级1.9(95%CI 1.2-2.9)。
  • 细胞学分级1、2、3级的中位疾病特异性生存分别为121个月(95%CI 57-185个月,估计值)、45个月(95%CI 29-87个月)、19个月(95%CI 1-44个月)。
  • 高分化与低分化神经内分泌肿瘤患者的中位生存分别为45个月和3个月(P<.001)。

临床怎么用

  • 在转移性胰腺神经内分泌肿瘤中,可借助细胞学标本评估分化与Ki-67分级以辅助预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival. METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms. RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<.001). CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. Cancer Cytopathol 2017;125:188-196. © 2016 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Sigel CS, Guo H, Sigel KM, et al. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. Cancer Cytopathol. 2017. PMID: 28094897. doi:10.1002/cncy.21817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。